Mostrando 2 resultados de: 2
Evaluation of different total leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a toll-like receptor-3 agonist to prevent cutaneous leishmaniasis
ArticleAbstract: BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. ThePalabras claves:L.Amazonensis, leishmaniasis, Poly (I:C), Whole-cell vaccineAutores:Bruna F.A., Cargnelutti D.E., Fernandes A.P., Germanó M.J., Lochedino A.L.S., Lozano E.S., Mackern-Oberti J.P., María Fernanda García Bustos, Salomón M.C., Sanchez M.V.Fuentes:scopusImmunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection
ArticleAbstract: Background/Purpose: A proper adjuvant has a relevant role in vaccine formulations to generate an effPalabras claves:BALB/c, Leishmania (Leishmania) amazonensis, Montanide ISA 763, R848, vaccinesAutores:Cargnelutti D.E., Celedon V., Cuello-Carrión F., María Fernanda García Bustos, Morea G., Salomón M.C., Scodeller E.A.Fuentes:scopus